Eurofins

Stefano Baila

Dr. Stefano Baila is the Managing Director of Support Biologics, specializing in cell and gene therapy, where he leads an expert team focused on expanding analytical and manufacturing capabilities for large-molecule therapies. He began his career over 20 years ago, working alongside pioneering leaders and institutions in the field.

Dr. Baila's career has bridged scientific innovation with manufacturing expertise, developing scalable solutions to make advanced therapies more accessible. His technical acumen has been instrumental in various strategic and commercial roles, all driven by a commitment to advancing cell and gene therapy.

Could you elaborate on how you've managed the complexities of automating manufacturing for commercial-scale cell and gene therapies, particularly from manufacturing and regulatory standpoints?

Cell and gene therapies have already demonstrated their potential as powerful tools for treating previously incurable diseases and improving patient outcomes. The next focus is on refining strategies to leverage these therapies more effectively.

The central challenge is making treatments both sustainable and affordable despite their complexity. Many therapies are patient-specific, requiring the handling of patient-derived materials, which must be worked on and returned to the same patient. Historically, this turnaround from collection to re-infusion has taken two to three weeks, and scaling to meet demand with hundreds of technicians is not feasible.

Over the past five to ten years, technology has advanced significantly. Bioreactors now maintain cells in optimal conditions, monitor them in-process and finetune their growth. AI plays a crucial role, enabling data collection during clinical phases to determine the best cell manufacturing strategies. This is especially important when a patient’s cells are less healthy or of lower quality than average. AI also helps predict whether the initial material can produce a successful therapy and identifies the most efficient manufacturing approaches. Automation reduces reliance on manual labor, while closed systems allow the process to occur in clean environments that don’t require as much stringent control, lowering costs.

Regulators are firm about ensuring patient safety and product quality, and they are also committed to helping the industry advance. They work to stay updated on new technologies, ensuring the regulatory framework supports the field's evolution.

Moving to downstream processes, how do you measure the real-world impact and outcomes of your cell and gene therapies?

Cell and gene therapies, like any drug in development, have defined clinical endpoints to assess efficacy. However, there is an increasing focus on real-world outcomes, considering not just clinical numbers but how these therapies improve patients' quality of life, helping them lead lives closer to those of healthy populations.

Given the high cost of these therapies, it's essential to assess their economic impact, or ‘health economics.’ This includes evaluating the long-term cost to healthcare systems with and without these therapies and patients' potential contributions to insurance or government-funded systems. Though complex, this analysis helps justify the therapy's cost by measuring its broader economic impact.

The industry is also innovating in reimbursement models. Some payment structures are now resultsbased, recognizing that patient response rates vary. This collaboration with payers ensures a fairer, more sustainable model where value is based on actual therapeutic outcomes.

Could you share insights into your leadership approach, specifically, how you foster a culture of innovation within your team while ensuring the rigorous standards required in biologics development?

Throughout my career, I’ve been fortunate to work with companies that prioritize rigorous quality standards, especially in patient-centric products where safety is the top priority. Identifying industry needs and finding efficient solutions without sacrificing quality is essential.

We proactively invest in two areas providing consulting and regulatory support to help clients identify challenges and offering platform solutions in analytics and manufacturing. By establishing pre-defined solutions and validated processes, we save time, patient material and costs.

We also ensure subject matter experts lead client interactions, guiding them to tailored solutions. As a leader, I focus on showcasing our team’s value and ensuring their contributions are properly recognized.

With over 15 years of experience in the cell and gene therapy space, what advancements do you anticipate will have a significant impact on patient care in the next decade or two?

The COVID-19 crisis accelerated healthcare advancements, particularly with RNA vaccines, highlighting the potential of RNA and lipid nanoparticles (LNPs) for gene delivery. Investment in LNP technology is shifting toward gene delivery, with future expansion to small molecules and biologics. This trend is expected to continue, improving delivery systems and vaccine-like approaches.

We are also gaining a deeper understanding of diseases, especially tumors, with AI playing a key role in identifying disease targets and treatment strategies. Cell and gene therapies have shown their potential, and the focus now is on refining their application and business models for specific diseases.

For some conditions, particularly rare diseases, a decentralized or point-of-care manufacturing approach may be necessary, as centralized models are not always feasible. With large pharmaceutical companies facing economic challenges, nonprofit institutions may play a larger role in ensuring treatment access.

Overall, I am optimistic about the future of cell and gene therapy, with significant advancements expected in the next 5–10 years, bringing solutions to patients in need.

What advice would you give to young professionals aiming to advance their careers in the cell and gene therapy sector?

My advice to new team members is rooted in two key principles.

First, build a solid scientific foundation. I recommend pursuing advanced education, ideally a PhD, to demonstrate the ability to understand complex science and challenge the status quo.

Second, seek international experience. Working abroad broadens your perspective, exposes you to diverse viewpoints and builds invaluable networks for career growth.

To succeed in this sector, focus on strengthening your scientific background, leveraging networks and pushing yourself outside your comfort zone through international experiences. These steps will foster both professional growth and a greater industry impact.